Mesoblast Acquires Culture Expanded Stem Cell Therapeutic Business from Osiris

Mesoblast Limited (OTC: MBLTY ) today announced the acquisition of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics (NASDAQ: OSIR ) by the Mesoblast Group. "The many commercial and strategic benefits of this transaction firm Mesoblast's leadership position in the global regenerative medicine industry," said Mesoblast